Horizon Pharma's Ravitchi (Glycerol Phenylbutyrate) Receives FDA Approval for Expansion of Age Range for in Patients with Urea Cycle Disorder (UCD)
Shots:
- The expansion approval of age range for ravicti is based on the study assessing safety- efficacy and PK in UCD infants patients aged ≤ 2mos.
- The study demonstrated safety and efficacy in children younger than two months- with stable ammonia levels relative to pre-study enrollment
- Ravitchi (glycerol phenylbutyrate) is an oral nitrogen binding agent liquid- indicated for chronic management of patients with urea cycle disorders (UCDs)
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
